ASCO® 2024 Summary: "Gynecologic Oncology Updates"

2024 ASCO® Annual Meeting Insights Hub

R. Salani

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

ASCO® 2024 Summary: "Gynecological Cancers Highlights"

2024 ASCO® Annual Meeting Insights Hub

M. Raza Mirza

ASCO® 2024 H&N Highlights: "Key Trial Updates in H&N Cancers"

2024 ASCO® Annual Meeting Insights Hub

N. Saba

ESMO 2024 Insights: Final OS With Niraparib as 1L Maintenance in Adv…

2024 ESMO Annual Meeting Insights Hub

B. Monk

Current Recommendations on Managing GI Adverse Reactions Associated …

Alberto Zambelli

Perspectives on the Effects of Time Toxicity in Breast Cancer Treatm…

Kathryn Post

J. Hutchinson

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

Oncologists' Perspectives on the Effects of Time Toxicity in Cancer …

Safiya Karim

ASCO® 2024 Summary: "News in Head&Neck Cancers"

2024 ASCO® Annual Meeting Insights Hub

P. Bossi

ESMO 2024 Summary: Head & Neck Cancer Take Home Messages

2024 ESMO Annual Meeting Insights Hub

P. Bossi

Management of Recurrent Ovarian Clear Cell Carcinoma

David Tan

ESMO 2024 Summary: Head & Neck Cancer Highlights

2024 ESMO Annual Meeting Insights Hub

N. Saba

Managing Dermatologic Toxicities: Cutaneous irAEs Associated with Im…

Cleveland Clinic Taussig Cancer Institute

R. Unwala

NOS ASCO® 2023 Review: Nasopharynx Cancer

Nebraska Oncology Society

E. Sherman

ESMO 2023 Summary: "Key Updates in Gynecological Cancers"

Insights from 2023 ESMO Annual Meeting

M. Raza Mirza

ESMO 2024 Insights: Rucaparib +/- Nivo as Maintenance in Newly Diagn…

2024 ESMO Annual Meeting Insights Hub

B. Monk

Infectious Complications of Checkpoint Inhibitors: Discussing Overla…

Cleveland Clinic Taussig Cancer Institute

Z. Yetmar